{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:59:38Z","timestamp":1790348378655,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Due to underlying chronic inflammation, inflammatory bowel disease (IBD) is associated with an increased risk of major adverse cardiovascular events (MACE). There is limited data on the role of cardiovascular (CV) risk factors and IBD medications on MACE. We aim to determine the association between MACE and IBD medications in a large national cohort of IBD patients with low baseline CV risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study between January 1, 2015 and November 15, 2023 using the TriNetX database. Using logistic regression analysis, IBD patients exposed to biologics and small molecules were assessed for outcomes of individual and composite MACE (myocardial infarction [MI], ischemic stroke, percutaneous coronary intervention [PCI]\/coronary artery bypass graft [CABG]). Outcomes were adjusted for demographics, non-advanced IBD therapies, statin use, CV risk factors, and prior history of coronary artery disease (CAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 113\u2009729 IBD patients with an average age of 42\u2009years and low prevalence of CV risk factors (5%-6%). Anti-TNF therapy was associated with a statistically significant decreased risk of composite MACE (adjusted OR [aOR] 0.795, 95% CI, 0.670-0.930, P\u2009=\u2009.005) and PCI\/CABG (aOR 0.56, 95% CI, 0.274-0.562, P\u2009=\u2009.002), and anti-integrin therapy was associated with a decreased risk of composite MACE (aOR 0.76, 95% CI, 0.580-0.980, P\u2009=\u2009.035). Anti-IL12\/23 and JAK inhibitors showed no increased risk of MACE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a cohort of young IBD patients with low CV risk, use of anti-TNF and anti-integrins is associated with a decreased risk of MACE, and there was no increased risk of MACE with JAK inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag039","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:24:53Z","timestamp":1777724693000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety of biologics and Janus kinase inhibitors in inflammatory bowel disease patients with low cardiovascular risk"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7017-0519","authenticated-orcid":false,"given":"Paraj","family":"Patel","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Medical College of Wisconsin , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omair","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-2949","authenticated-orcid":false,"given":"Divyanshu","family":"Mohananey","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin Medical College of Wisconsin Cardiovascular Center, , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saffia","family":"Bajwa","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin Department of Medicine, , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Khani","sequence":"additional","affiliation":[{"name":"Health Informatics Program, Zilber School of Public Health, University of Wisconsin-Milwaukee , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Luo","sequence":"additional","affiliation":[{"name":"Health Informatics Program, Zilber School of Public Health, University of Wisconsin-Milwaukee , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Stein","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Medical College of Wisconsin , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursimran S","family":"Kochhar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Allegheny Health Network , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana G","family":"Hashash","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mayo Clinic in Florida , Jacksonville, FL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Mansoor","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Liver Disease, University Hospitals Cleveland Medical Center, Case Western Reserve University , Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond K","family":"Cross","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetika","family":"Sinh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Medical College of Wisconsin , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2026092510111161800_otag039-B1","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/ibd\/izy354","article-title":"Risk of myocardial infarction in inflammatory bowel disease: a population-based national study","volume":"25","author":"Panhwar","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026092510111161800_otag039-B2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/ajg.2011.63","article-title":"Inflammatory bowel disease is associated with an increased incidence of cardiovascular events","volume":"106","author":"Yarur","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2026092510111161800_otag039-B3","doi-asserted-by":"publisher","first-page":"S-6","DOI":"10.1016\/S0016-5085(22)60016-7","article-title":"Incidence of cardiovascular disease in veterans with inflammatory bowel disease: data from a large cohort of United States veterans from 2002 to 2015","volume":"162","author":"Sinh","year":"2022","journal-title":"Gastroenterology"},{"key":"2026092510111161800_otag039-B4","doi-asserted-by":"publisher","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional, and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"2026092510111161800_otag039-B5","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"-Virani","year":"2020","journal-title":"Circulation"},{"key":"2026092510111161800_otag039-B6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/apt.17932","article-title":"Impact of inflammatory bowel disease on the risk of acute coronary syndrome: a Swedish nationwide cohort study","volume":"59","author":"Eriksson","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092510111161800_otag039-B7","doi-asserted-by":"publisher","first-page":"e56944","DOI":"10.1371\/journal.pone.0056944","article-title":"Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke, and cardiovascular death\u2014a Danish nationwide cohort study","volume":"8","author":"Kristensen","year":"2013","journal-title":"PLoS One"},{"key":"2026092510111161800_otag039-B8","first-page":"204","article-title":"Cardiovascular comorbidities and inflammatory bowel disease: causes and consequences","volume":"20","author":"Sinh","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026092510111161800_otag039-B9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026092510111161800_otag039-B10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2026092510111161800_otag039-B11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026092510111161800_otag039-B12","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.cgh.2021.12.030","article-title":"Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn\u2019s disease in the CELEST extension study","volume":"20","author":"D\u2019Haens","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092510111161800_otag039-B13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/apt.17570","article-title":"Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: a propensity-matched cohort study","volume":"58","author":"Kochhar","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092510111161800_otag039-B14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ibd\/izae267","article-title":"Biologics and oral small molecules are not associated with increased major adverse cardiovascular events or venous thromboembolism in inflammatory bowel disease","volume":"31","author":"Qapaja","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026092510111161800_otag039-B15","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.eclinm.2022.101619","article-title":"Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks","volume":"53","author":"Wang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026092510111161800_otag039-B16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1159\/000521025","article-title":"Exercise-based cardiac rehabilitation associates with lower major adverse cardiovascular events in people with stroke","volume":"51","author":"Buckley","year":"2022","journal-title":"Cerebrovasc Dis"},{"key":"2026092510111161800_otag039-B17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/gutjnl-2019-318932","article-title":"Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study","volume":"69","author":"Kirchgesner","year":"2020","journal-title":"Gut"},{"key":"2026092510111161800_otag039-B18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026092510111161800_otag039-B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092510111161800_otag039-B20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"2026092510111161800_otag039-B21","doi-asserted-by":"publisher","first-page":"e006283","DOI":"10.1161\/CIRCIMAGING.117.006283","article-title":"Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis","volume":"10","author":"Ikonomidis","year":"2017","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag039\/68236892\/otag039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/2\/otag039\/68236892\/otag039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/2\/otag039\/68236892\/otag039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:11:17Z","timestamp":1790345477000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag039\/8671589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag039","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]},"article-number":"otag039"}}